Harte Hanks vs OptimizeRx
HHS and OPRX side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How HHS and OPRX compare
OptimizeRx is the larger company, worth 4.6 times as much as Harte Hanks ($138M against $29.9M).
Harte Hanks grew revenue faster over the last twelve months (−7.3% versus −14.0% for OptimizeRx).
OptimizeRx keeps more of each dollar of sales as profit, with a net margin of 5.3% compared with −3.2% at Harte Hanks.
OptimizeRx scores higher on the StockData Score (11 against 3 for Harte Hanks), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | HHS | OPRX |
|---|---|---|
| Size and price | ||
| Market cap | $29.9M | $138M |
| Share price | $4.01 | $7.34 |
| Change, 1 year | 37.3% | −54.6% |
| Change, 5 years | −52.1% | −89.8% |
| Beta (5Y) | 0.71 | 1.94 |
| Employees | 1,719 | 104 |
| StockData Score | ||
| Total score | 3 | 11 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 2 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 28.2× |
| P/S | 0.2× (better) | 1.5× |
| P/B | 2.1× | 1.0× (better) |
| EV/EBITDA | – | 8.2× |
| P/FCF | – | 7.0× |
| FCF yield | −32.4% | 14.4% (better) |
| Fair value | – | $10.52 |
| Margin of safety | – | 30.2% |
| Growth | ||
| Revenue growth (TTM) | −7.3% (better) | −14.0% |
| Revenue growth, 5Y average | −2.0% | 20.4% (better) |
| Net income growth (TTM) | – | 14656% |
| Profitability | ||
| Gross margin | – | 75.3% |
| Operating margin | −4.6% | 12.2% (better) |
| Net margin | −3.2% | 5.3% (better) |
| FCF margin | −6.3% | 21.1% (better) |
| Return on equity | −29.0% | 3.9% (better) |
| Return on invested capital | −35.9% | 5.5% (better) |
| Financial health | ||
| Debt / equity | 0.45 | 0.10 (better) |
| Net debt / EBITDA | – | −0.61 |
| Interest coverage | – | 3.1× |
| Current ratio | 1.23 | 5.06 (better) |
| Altman Z-score | 14.66 (better) | 3.39 |
| Piotroski F-score | 4 | 8 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 29.1% | 59.6% |
| Held by insiders | 39.8% | 19.4% |
| Insider net buying, 12 months | – | −$18.8K |
| Short interest, % of float | 0.98% | 7.8% |
Go deeper
- HHS stock overview
- HHS income statement
- HHS valuation and score
- OPRX stock overview
- OPRX income statement
- OPRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.